Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity

Abstract

Objective. To review the experience of treatment with etoposide phosphate in patients with acute etoposide hypersensitivity treated in a large tertiary referral center hospital specializing in curable malignancies.

Case summaries. The cases of 6 patients with advanced malignancies who experienced acute etoposide hypersensitivity are documented. There were 3 male and 3 female patients and their ages ranged from 16 to 68. Four patients had curable malignancies with trophoblast tumors or germ cell tumors and two were receiving palliative chemotherapy for other malignancies. All of the 6 patients who experienced etoposide hypersensitivity developed their symptoms in the first few minutes of the initial infusion. The most common symptoms were chest pain, facial flushing, and bronchospasm. All of the patients had emergency treatment with discontinuation of the infusion and usually the administration of hydrocortisone and chlorpheniramine, which lead to the rapid resolution of their symptoms.

For the next cycle of chemotherapy each patient was rechallenged with etoposide phosphate, with steroid cover given in only two of the cases. None of the 6 patients experienced any hypersensitivity symptoms on treatment with etoposide phosphate and in one the steroids were withdrawn for all the subsequent cycles. The 4 patients with curable malignancies all remain disease free, while the 2 palliative patients obtained significant control of their disease.

Discussion. Etoposide is one of the most important chemotherapy drugs in the treatment of many curable malignancies but an acute hypersensitivity reaction occurs in around 1% of patients. Retreatment with etoposide in these patients is difficult and generally alternative drugs/regimens have to be used. A small number of case reports have suggested that etoposide phosphate can be safely used in these patients and 6 cases have been found in the pharmacy records where this has been done. In all of the patients, treatment with etoposide phosphate proceeded without any symptoms or the use of repeated steroid cover in 5 of the 6 patients.

Conclusion. Etoposide hypersensitivity is a rare clinical problem and responds promptly to drug discontinuation, steroids, and chlorpheniramine. Patients with previous etoposide hypersensitivity can safely be treated with etoposide phosphate and do not need any additional hypersensitivity prophylaxis. J Oncol Pharm Practice (2008) 14: 51—55.

Keywords

chemotherapy hypersensitivity etoposide etoposide phosphate

Get full access to this article

View all access options for this article.

References

Williams SD , Birch R. , Einhorn LH , Irwin L. , Greco FA , Loehrer PJ Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 4: 1435—40.

Bower M. , Newlands ES , Holden L. , Short D. , Brock C. , Rustin GJ , Begent RH , Bagshawe KD EMA-CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997 ; 15: 2636—43.

Newlands ES , Mulholland PJ , Holden L. , Seckl MJ , Rustin GJ Etoposide and cisplatin-etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA-cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000; 18: 854—59.

O'Dwyer PJ , Weiss RB Hypersensitivity reactions induced by etoposide . Cancer Treat Rep 1984; 68: 959—61.

O'Brein MER , Souberbielle BE Allergic reactions to cytotoxic drugs — an update. Annals Oncol. 1992; 3: 605—10.

Weiss RB Hypersensitivity reactions. In: Perry MC. editor. The chemotherapy source book. 2nd edn, Baltimore; Williams & Wilkins, 1996: 613—34.

Hudson MM , Weinstein HJ , Donaldson SS et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993; 11: 1080—4.

Hoetelmans RM , Schornagel JH , ten Bokkel Huinink WW , Beijen JH Hypersensitivity reactions to etoposide. Ann Pharmacother 1996 ; 30: 367—71.

Siderov J. , Prasad P. , De Boer R. , Desai J. Safe administration of etoposode phosphate after hypersensitivity reaction to intravenous etoposide. British Journal of Cancer 2002; 86: 12—13.

10.

Bower M. , Brock C. , Gulliford T. , O'Reilly, SM , Smith DB , Newlands ES A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma. Cancer Chemother Pharmacol 1996; 38: 106—09.

11.

Bower M. , Newlands ES , Holden L. , Rustin GJ , Begent RH Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB-ACE chemotherapy. Ann Oncol 1997; 8: 477—83.

12.

Fukuoka M. , Furuse K. , Saijo N. , Nishiwaki Y. , Ikegami H. , Tamura T. , Shimoyama M. , Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855—61.

13.

Bernstein BJ , Troner MB Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide. Pharmacotherapy 1999; 19: 989—91.

14.

Tester WJ , Cohn JB , Fleekop PD , Rabinowitz MS , Lieberman JS Successful rechallenge to etoposide after an acute vasomotor response . J Clin Oncol 1990; 8: 1600—01.

15.

Athanassiou AE , Bafaloukos D. , Pectasides D. , Dimitriadis M. Acute vasomotor response — a reaction to etoposide. J Clin Oncol 1988; 6: 1204—05.